None

Novo Nordisk's "Liraglutide" Effective At Inducing Weight Loss

Novo Nordisk has just announced that their drug liraglutide is extremely effective at inducing weight loss among people suffering from type 2 diabetes. In a 56-week long double-blind phase 3a clinica...

Liraglutide safe, effective in type 2 diabetics with liver injury

NEW YORK (Reuters Health) - Treatment with liraglutide (Victoza) 1.8 mg for 26 weeks was well tolerated and improved liver enzymes in type 2 diabetics enrolled in six trials of the Liraglutide Eff...

Efficacy of Liraglutide in Obese Type 2 Diabetes

Is liraglutide use associated with persistent weight loss? Cardiovascular Diabetology

Liraglutide Edge Over Exenatide, but GI Side Effects Doubled

Once-daily liraglutide had the edge over once-weekly exenatide in a new head-to-head comparison of the two GLP-1 agonists in type 2 diabetes, but more patients on liraglutide had gastrointestinal side...

Liraglutide's Big(ger) Picture

Novo Nordisk thinks a growing data package for 3 mg liraglutide will clear FDA's regulatory hurdles to treat obesity in patients with diabetes and other co-morbidities.

[Articles] Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

Both once daily liraglutide and once weekly exenatide led to improvements in glycaemic control, with greater reductions noted with liraglutide. These findings, plus differences in injection frequency...

Albiglutide vs Liraglutide: Better Tolerated, Less Effective

Patients with type 2 diabetes that is not controlled with first-line therapy had fewer gastrointestinal adverse effects with albiglutide, but it was not superior to liraglutide. Medscape Medical Ne...

Liraglutide and insulin boost metformin in diabetics

NEW YORK (Reuters Health) - Should metformin become insufficient in type 2 diabetics, adding liraglutide -- and insulin detemir, if necessary -- provides good results, according to a May 18 online...

Metabolism and Excretion of the Once Daily Human GLP-1 Analog liraglutide in Healthy Male Subjects and its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase.

Liraglutide is a novel once-daily human glucagon-like peptide (GLP)-1 analog in clinical use for the treatment of type 2 diabetes. To study metabolism and excretion of [(3)H]-liraglutide, a single sub...

Liraglutide: a review of its use in the management of type 2 diabetes mellitus.

Liraglutide (Victoza®) is a subcutaneously administered glucagon-like peptide-1 (GLP-1) receptor agonist produced by recombinant DNA technology and used as an adjunct to diet and exercise in the trea...

The efficacy and safety of liraglutide.

Aim of the review To systematically analyze the efficacy and safety of liraglutide for the treatment of diabetes mellitus in comparison to other mono- and combination therapies. Method PubMed (any dat...

Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats.

Liraglutide, an analog of glucagon-like peptide-1 (GLP-1), is an effective anti-diabetic agent with few side effects. Since native GLP-1 exerts vascular effects, we investigated changes in pancreatic...

Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide.

A 59-year old man with moderate and stable psoriasis through 15 years was admitted to our Department with inadequately controlled type 2 diabetes. Treatment was initiated with the glucagon-like pepti...